Medical Licensing (MD/DO) · Independent exam preparation
ABOG Maternal-Fetal Medicine Qualifying Examination: Focused Preparation Guide Study Guide
Practise maternal stabilization, pregnancy management, fetal assessment and genetic counseling for ABOG’s written MFM Qualifying Examination through focused cases.
By CertMedbry · Updated 15 October 2026
Practise recognizing maternal deterioration, selecting pregnancy-specific treatment, interpreting fetal surveillance, and explaining genetic risk. This selective guide develops 60 clinical concepts across five ABOG domains, followed by original questions and flashcards. The official competency outline defines the full examination scope; additional topics in that outline require study beyond these selections.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification stage does this guide address?
The written Maternal-Fetal Medicine Qualifying Examination within ABOG’s physician subspecialty certification pathway. It does not address the separate oral Certifying Examination or continuing certification. Subspecialty board certification is distinct from medical licensure.
ABOG subspecialty-certification exam blueprint listing · ABOG Maternal-Fetal Medicine competency blueprint
How many official questions are there, and how many are scored or pretest items?
ABOG’s 2026 Subspecialty Qualifying Examination bulletin specifies 230 single-best-answer multiple-choice questions for the MFM examination. The scored/pretest breakdown remains unspecified here. This resource contains 20 independent practice questions and 20 flashcards. Source: [2026 Subspecialty Qualifying Examination bulletin](https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_1).
What are the examination duration, delivery method, and adaptive features?
ABOG’s 2026 bulletin describes an approximately 3-hour-45-minute examination administered through Pearson VUE testing arrangements. Whether adaptive features apply remains unspecified here. Source: [2026 Subspecialty Qualifying Examination bulletin](https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_1).
Which question styles do these exercises use?
The official 2026 examination uses single-best-answer multiple-choice questions. These independent clinical exercises use four answer options per question; the official number of answer options remains unspecified here. The exercises do not reproduce an official examination interface. Source: [2026 Subspecialty Qualifying Examination bulletin](https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_1).
Which blueprint applies, and what is its effective date?
This guide follows the ABOG MFM competency blueprint linked from the subspecialty-certification listing. Its URL contains a 2026 directory, but the document states no explicit effective or update date. The directory alone does not establish implementation timing.
ABOG subspecialty-certification exam blueprint listing · ABOG Maternal-Fetal Medicine competency blueprint
Are official domain percentages available, and does this guide cover the entire outline?
No numeric domain weights are stated in the competency blueprint. The allocations here are editorial choices, not official percentages. All five domains appear, but 60 concepts are selective. The official outline defines the full scope, including additional neurologic, surgical, anesthetic, placental, ultrasound, and fetal conditions beyond these selections.
This independent educational guide addresses the United States physician subspecialty Maternal-Fetal Medicine Qualifying Examination administered by ABOG. The oral Certifying Examination is a separate subsequent step. These learning materials are not official ABOG examination items.
Outline used: ABOG Maternal-Fetal Medicine competency blueprint linked from its current subspecialty-certification listing, preserved in trusted successful retrievals dated 2026-10-08. The PDF is served from the issuer's 2026 resource path, but its readable content states neither an explicit effective/update date nor numeric domain weights. The workbook's subspecialty credential label is mapped to the written Maternal-Fetal Medicine Qualifying Examination for this MCQ preview; the oral Certifying Examination is a distinct subsequent certification step. Fresh issuer retrieval limitations are documented in notes.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Nonobstetric Pregnancy Complicationsnot stated
1.Why does preconception glycemic control prevent diabetic embryopathy?
Hyperglycemia during organogenesis increases congenital anomaly risk, so glucose optimization must begin before conception rather than after the anatomy survey. ADA guidance recommends an A1C below 6.5% before pregnancy when achievable safely. Counseling combines effective contraception until treatment is optimized, medication review, and assessment of diabetic complications. The discriminating clue is timing: a reassuring glucose profile later in pregnancy cannot undo exposure during early embryonic development.
Apply it
A patient with type 1 diabetes and an A1C of 8.4% wants pregnancy immediately. Explain early embryonic risk, establish a safer glucose plan, review medications, and discuss contraception while preparing for conception.
Common pitfall: Waiting until pregnancy confirmation to address glycemia misses part of organogenesis; an excellent third-trimester A1C does not eliminate risk from early hyperglycemic exposure.
ADA: Management of Diabetes in Pregnancy—Standards of Care in Diabetes—2026
2.When should diabetic retinopathy be assessed around pregnancy?
Pregnancy can accelerate existing diabetic retinopathy, and rapid improvement in glycemia may contribute to progression in susceptible patients. For preexisting type 1 or type 2 diabetes, ADA recommends eye assessment before pregnancy and in the first trimester, followed by surveillance during each trimester and through the first postpartum year. Examination frequency should be individualized by retinal findings, retinopathy severity, and the eye care professional. Visual symptoms are not a reliable screening requirement. Retinal assessment complements glucose optimization rather than providing a reason to leave significant hyperglycemia untreated.
Apply it
A patient with longstanding type 1 diabetes presents at nine weeks without visual symptoms and has not had a recent retinal examination. Arrange ophthalmic evaluation now and establish surveillance during each trimester and through the first postpartum year, with frequency individualized by the eye care professional according to retinal findings.
Common pitfall: Absence of blurred vision does not exclude retinopathy. Gestational diabetes alone does not carry the same indication for pregnancy-related retinopathy screening as preexisting diabetes.
ADA: Management of Diabetes in Pregnancy—Standards of Care in Diabetes—2026
3.Which glucose-lowering treatment is preferred when medication is needed?
Insulin is essential for type 1 diabetes and is the preferred medication for type 2 diabetes and gestational diabetes during pregnancy in ADA guidance. Insulin does not cross the placenta in clinically meaningful amounts, whereas metformin and glyburide cross it. Medication selection therefore includes fetal exposure and the ability to meet pregnancy glucose targets. Treatment must still account for nutrition, glucose patterns, hypoglycemia risk, and the patient’s ability to administer therapy.
Apply it
A patient with gestational diabetes has persistent fasting elevations despite nutrition therapy and activity. Discuss insulin initiation and monitoring, explaining why familiarity with an oral medication does not make it the preferred pregnancy treatment.
Common pitfall: Placental transfer distinguishes oral agents from insulin, but it does not mean every prior oral exposure caused harm or that counseling should be punitive.
ADA: Management of Diabetes in Pregnancy—Standards of Care in Diabetes—2026
4.How does pregnancy change medication selection for systolic heart failure?
Treatment depends on whether chronic systolic heart failure is compensated or acutely decompensated. For compensated chronic disease, SMFM supports continuing selected beta blockers such as metoprolol, carvedilol, or bisoprolol, with cardiology-guided therapy. During acute decompensated left ventricular failure, SMFM recommends against beta blockade because its negative inotropic effect can impair cardiac output. Acute left ventricular failure during pregnancy requires stabilization, furosemide for congestion, and hydralazine or isosorbide dinitrate for pregnancy-compatible afterload reduction. ACE inhibitors, angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitors, and spironolactone should be discontinued during pregnancy.
Apply it
A newly pregnant patient with reduced ejection fraction takes an ACE inhibitor and develops pulmonary congestion. Assess urgently for acute decompensation, discontinue pregnancy-incompatible therapy, and coordinate furosemide and appropriate afterload reduction with cardiology. If acutely decompensated, stabilize without beta blockade; continuation of selected beta blockers applies to compensated chronic disease.
Common pitfall: Pregnancy compatibility does not make a beta blocker appropriate during acute decompensated left ventricular failure. Avoiding fetal drug toxicity must also include effective replacement treatment for maternal congestion and impaired cardiac output.
SMFM Consult Series #73: Diagnosis and management of right and left heart failure during pregnancy and postpartum · SMFM_Consult_Series__73__Diagnosis_and_management_of_right_and_left.pdf
5.How should delivery be planned for a patient with heart failure?
Delivery planning in heart failure depends on clinical stability, ventricular function, hemodynamic burden, and obstetric indications. Stable disease generally permits planned vaginal delivery with coordinated anesthesia and monitoring. Cesarean delivery is not automatically protective because surgery introduces bleeding, thrombotic, and fluid-shift risks. Decompensation changes the assessment and may require expedited delivery or additional circulatory support. A multidisciplinary plan should specify intrapartum management and the vulnerable immediate postpartum period.
Apply it
A patient with compensated cardiomyopathy has no obstetric indication for cesarean delivery. Develop a monitored vaginal birth plan with cardiology and anesthesia, including postpartum observation and clear triggers for escalation if symptoms worsen.
Common pitfall: Reduced ejection fraction alone does not establish that cesarean delivery is safer. The route must reflect current physiology and obstetric circumstances rather than diagnosis alone.
6.Why can heart failure worsen after delivery?
Delivery does not immediately remove cardiovascular stress. Changes in venous return and mobilization of extracellular fluid can increase cardiac filling pressures postpartum, exposing limited ventricular reserve. New orthopnea, hypoxemia, or pulmonary edema therefore requires assessment rather than attribution to ordinary recovery. Postpartum management includes volume assessment, appropriate heart failure therapy, and review of lactation compatibility. Medication choices may broaden after birth, but breastfeeding requires drug-specific evaluation rather than a universal prohibition.
Apply it
Two days after birth, a patient with cardiomyopathy develops orthopnea and falling oxygen saturation. Assess pulmonary congestion and cardiac function promptly, review fluid balance, and adjust treatment rather than assuming delivery resolved the cardiac risk.
Common pitfall: Normal postpartum fatigue does not explain hypoxemia or orthopnea. Conversely, breastfeeding status alone is not a reason to withhold all disease-modifying cardiac treatment.
7.Which hepatitis B tests distinguish infection from immunity?
Hepatitis B surface antigen indicates current infection, surface antibody indicates immunity, and total core antibody indicates exposure to natural infection rather than vaccination alone. SMFM recommends a triple panel at the initial prenatal visit when prior appropriate testing is undocumented. Surface antigen testing remains important in each pregnancy. A positive infection screen requires further evaluation, including viral load, because infectivity and eligibility for transmission-reduction treatment cannot be inferred from surface antibody alone.
Apply it
An obstetric patient has no documented prior hepatitis B testing and reports childhood vaccination. Obtain the recommended screening panel; a vaccination history alone does not document the patient’s current infection and immunity profile.
Common pitfall: Do not interpret surface antibody as evidence of active infection or assume core antibody results from vaccination. The three markers answer different clinical questions.
SMFM Consult Series #69: Hepatitis B in pregnancy: updated guidelines
8.When does hepatitis B viral load warrant antenatal antiviral prophylaxis?
High maternal hepatitis B viral load increases transmission risk despite appropriate neonatal prophylaxis. SMFM recommends tenofovir treatment in the third trimester, generally beginning at 28–32 weeks, when HBV DNA exceeds 200,000 IU/mL. This intervention supplements rather than replaces newborn vaccination and hepatitis B immune globulin. Separate maternal indications for chronic hepatitis treatment also require assessment, so a transmission-prevention threshold does not define every reason to treat maternal infection.
Apply it
At 28 weeks, an HBsAg-positive patient has HBV DNA of 900,000 IU/mL. Discuss tenofovir prophylaxis and establish a newborn immunoprophylaxis plan, while coordinating evaluation of the mother’s own liver disease and follow-up.
Common pitfall: A low viral load does not cancel neonatal prophylaxis. Conversely, surface antigen positivity alone does not establish that the transmission-prevention antiviral threshold is met.
SMFM Consult Series #69: Hepatitis B in pregnancy: updated guidelines
9.How are newborn prophylaxis and breastfeeding coordinated with maternal hepatitis B?
Infants born to an HBsAg-positive parent should receive hepatitis B vaccine and hepatitis B immune globulin within 12 hours of birth. These provide active and passive protection through different mechanisms. Maternal antiviral use does not eliminate either neonatal intervention. SMFM supports breastfeeding after appropriate infant immunoprophylaxis and does not recommend cesarean delivery solely to reduce hepatitis B transmission. Delivery planning should make prophylaxis reliably available without unnecessarily restricting feeding choices.
Apply it
An HBsAg-positive patient taking tenofovir plans vaginal delivery and breastfeeding. Confirm immediate newborn vaccine and immune globulin availability, explain their complementary roles, and support breastfeeding once the infant receives appropriate birth prophylaxis.
Common pitfall: Neither maternal tenofovir nor elective cesarean delivery substitutes for newborn immunoprophylaxis. Maternal hepatitis B infection alone is not a reason to prohibit breastfeeding.
SMFM Consult Series #69: Hepatitis B in pregnancy: updated guidelines
10.How do baseline and risk-based thromboprophylaxis differ after cesarean delivery?
SMFM recommends sequential compression devices for every cesarean delivery, beginning before surgery and continuing until fully ambulatory. A previous deep venous thrombosis or pulmonary embolism adds an indication for pharmacologic prophylaxis for six weeks postpartum. Low-molecular-weight heparin is the preferred prophylactic agent when appropriate. Medication initiation must account for hemostasis, renal function, and neuraxial procedural timing. The universal mechanical intervention and the additional risk-based medication course address different portions of the perioperative and postpartum risk.
Apply it
A patient with a remote pulmonary embolism undergoes cesarean delivery. Apply compression devices before surgery and establish six weeks of postpartum pharmacologic prophylaxis, coordinating initiation with bleeding assessment and anesthesia.
Common pitfall: Stopping prophylaxis at discharge is insufficient for this prior-VTE population. Universal compression devices do not establish that every cesarean patient requires six weeks of anticoagulation.
SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery
11.When does an infected nonobstetric surgical source require urgent intervention?
Sepsis from a surgically controllable nonuterine source requires prompt source identification and emergency source control when indicated. Broad-spectrum antibiotics and circulatory resuscitation proceed alongside surgical assessment; they do not replace drainage or removal of infected tissue when that is necessary to control the infection. Pregnancy does not make delivery a substitute for treatment of an abdominal or postoperative infectious source. The decisive question is which intervention controls the actual source, with obstetric and anesthesia teams supporting maternal stabilization.
Apply it
A pregnant patient has hypotension, organ dysfunction, and an identified infected postoperative collection. Begin sepsis treatment and obtain urgent surgical assessment for drainage rather than waiting for antibiotics alone to resolve a source requiring intervention.
Common pitfall: Transient improvement in blood pressure does not prove source control. Delivering a fetus does not drain a nonuterine collection or remove infected postoperative tissue.
SMFM Consult Series #67: Maternal sepsis—full guideline · ABOG Maternal-Fetal Medicine competency blueprint
12.When does inherited thrombophilia justify extended prophylaxis after cesarean?
An inherited thrombophilia can increase postpartum thrombotic risk even without a previous clinical clot. SMFM recommends mechanical prophylaxis plus six weeks of pharmacologic prophylaxis after cesarean delivery for patients with an inherited thrombophilia, whether classified as high or low risk, despite no personal thrombosis history. This recommendation concerns postoperative prevention in a defined population. It does not establish a reason to screen every pregnant patient for thrombophilia or treat an acute suspected embolism prophylactically.
Apply it
A patient with documented inherited thrombophilia but no prior thrombosis requires cesarean delivery. Include extended postpartum pharmacologic prophylaxis in the plan rather than limiting prevention to the compression devices used during the hospital admission.
Common pitfall: No prior clot does not equal average risk in this specific setting. Prophylactic anticoagulation also must not be confused with therapeutic treatment of confirmed thrombosis.
SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery
Critical Carenot stated
13.How do organ dysfunction and infection source guide maternal sepsis management?
Consider maternal sepsis when suspected or confirmed infection accompanies otherwise unexplained organ dysfunction, even without fever. Hypotension, confusion, hypoxemia, or oliguria can be more decisive than temperature. Identify the source while resuscitation begins. Suspected or confirmed uterine sepsis requires prompt delivery or evacuation for source control regardless of gestational age. Nonuterine sepsis alone does not mandate delivery: treat the actual source and assess separate obstetric indications. Fetal abnormalities during maternal shock may reflect impaired maternal oxygenation and perfusion.
Apply it
An afebrile postpartum patient has foul discharge, confusion, hypotension, and oliguria. Treat suspected sepsis immediately and investigate a uterine source; do not wait for fever or assume antibiotics remove the need to evacuate infected retained contents.
Common pitfall: Fever is neither necessary nor sufficient for sepsis. Conversely, pneumonia-associated sepsis does not create the same source-control indication for uterine evacuation as an infected uterus.
SMFM Consult Series #67: Maternal sepsis—full guideline · SMFM Consult Series #67: Maternal sepsis
14.When should antibiotics follow cultures in suspected maternal septic shock?
Sepsis and septic shock are medical emergencies. SMFM recommends prompt broad-spectrum antimicrobial treatment, ideally within one hour of recognition when septic shock or a high likelihood of sepsis is present. Obtain appropriate cultures first if doing so will not substantially delay treatment, and measure serum lactate to assess illness severity. Culture collection supports later targeting, but the immediate priority is effective therapy against likely pathogens while the source and organ dysfunction are assessed.
Apply it
A pregnant patient has suspected pyelonephritis, hypotension, and altered mentation. Draw cultures promptly while preparing broad-spectrum antibiotics, but begin treatment without waiting for culture results or completion of nonessential diagnostic imaging studies.
Common pitfall: Cultures guide subsequent narrowing; they are not a prerequisite that justifies a prolonged antibiotic delay. Lactate measurement likewise should proceed alongside treatment rather than postpone it.
15.How should fluids and vasopressors be coordinated in maternal septic shock?
For maternal sepsis with hypotension or suspected hypoperfusion, SMFM recommends early administration of 1–2 liters of balanced crystalloid within the first three hours, with frequent reassessment. Fluid responsiveness asks whether more preload improves cardiac output; fluid tolerance asks whether that volume causes harmful congestion. Dynamic assessment is preferable to static filling pressures alone. Persistent hypotension after initial resuscitation, especially with worsening oxygenation during additional fluid, supports norepinephrine as the first-line vasopressor rather than repeated ineffective boluses.
Apply it
After initial balanced crystalloid, a septic patient remains hypotensive and develops increasing oxygen requirements with further fluid. Reassess cardiac response and congestion, initiate norepinephrine with critical care support, and continue antibiotics and source control.
Common pitfall: Tachycardia alone does not prove volume depletion. Concern about pulmonary edema should prompt reassessment and targeted support rather than either unlimited fluid or withholding all initial resuscitation.
SMFM Consult Series #67: Maternal sepsis—full guideline · SMFM Consult Series #67: Maternal sepsis
16.How should active massive obstetric hemorrhage change resuscitation priorities?
Ongoing major hemorrhage with circulatory compromise requires immediate bleeding control and restoration of circulating blood components in parallel. Activate the massive hemorrhage response and involve obstetrics, anesthesia, and transfusion services early. Red-cell replacement supports oxygen-carrying capacity, while plasma, platelets, and fibrinogen replacement address accompanying hemostatic deficits. Crystalloid alone cannot replace these functions. Assess the bleeding source and coagulation status repeatedly because mechanical bleeding and coagulopathy can coexist and require different interventions.
Apply it
A patient has brisk postpartum hemorrhage, hypotension, and diffuse oozing during cardiopulmonary deterioration. Activate massive transfusion resources while controlling obstetric bleeding and assessing coagulation rather than escalating crystalloid alone.
Common pitfall: Blood pressure improvement does not establish that hemorrhage is controlled. Transfusion also cannot replace definitive treatment of an ongoing bleeding source.
SMFM: Checklist for initial management of amniotic fluid embolism—Updated 2026 · ABOG Maternal-Fetal Medicine competency blueprint
17.Which findings distinguish systemic coagulopathy from an isolated bleeding site?
Diffuse bleeding from venipuncture sites, wounds, and multiple surfaces suggests a systemic hemostatic defect rather than a single untreated vessel. In obstetric collapse, including suspected amniotic fluid embolism, rapidly developing consumptive coagulopathy can accompany the primary emergency. Assess platelet count, fibrinogen, and coagulation times serially and replace deficient components through the hemorrhage response while treating the underlying cause. Red cells restore oxygen transport but do not by themselves correct platelet or coagulation-factor depletion.
Apply it
After initial uterine bleeding is controlled, a patient continues to ooze from intravenous sites and an incision. Reassess coagulation immediately and coordinate component replacement rather than assuming persistent bleeding must be uterine atony.
Common pitfall: A local procedure cannot correct a systemic coagulation deficit. Conversely, identifying coagulopathy should not stop the search for a concurrent mechanical bleeding source.
SMFM: Checklist for initial management of amniotic fluid embolism—Updated 2026 · ABOG Maternal-Fetal Medicine competency blueprint
18.Why is falling oxygen saturation especially dangerous in pulmonary hypertension?
Hypoxemia produces pulmonary vasoconstriction, increasing pulmonary vascular resistance and right ventricular afterload. A failing right ventricle may then deliver less blood through the lungs, reducing left ventricular filling and systemic cardiac output. SMFM’s heart failure guidance recommends maintaining oxygen saturation at least 90%, preferably at least 95%, in this right-heart-failure context. Interpret the saturation trend with oxygen requirements and hemodynamics: a maintained saturation achieved only with increasing support still represents deterioration.
Apply it
A pregnant patient with pulmonary arterial hypertension develops falling saturation and hypotension. Correct hypoxemia promptly while assessing right ventricular function and perfusion; the oxygen change can worsen the circulatory problem rather than merely accompany it.
Common pitfall: Do not apply this disease-specific minimum as a universal target for every obstetric respiratory condition. A single acceptable saturation does not establish stability when respiratory support is escalating.
SMFM_Consult_Series__73__Diagnosis_and_management_of_right_and_left.pdf
19.How can elevated venous pressure coexist with inadequate cardiac output?
Right ventricular failure can raise systemic venous pressure while reducing forward flow through the pulmonary circulation. Reduced pulmonary flow decreases left ventricular filling and systemic cardiac output, so edema or an elevated central venous pressure does not establish adequate perfusion. Interpret pressure alongside echocardiographic right ventricular function, urine output, and other perfusion findings. Elevated estimated right ventricular systolic pressure can reflect pulmonary hypertension, fluid overload, or ventricular dysfunction and requires corroboration rather than serving as a stand-alone diagnosis.
Apply it
A hypotensive patient has venous congestion, oliguria, and echocardiographic right ventricular dysfunction. Recognize that congestion and low output can coexist; assess the cause and volume balance rather than reflexively treating hypotension with repeated large fluid boluses.
Common pitfall: A high filling pressure is not a measurement of effective forward flow. An isolated elevated echocardiographic pressure estimate also does not identify the cause of pulmonary hypertension.
SMFM_Consult_Series__73__Diagnosis_and_management_of_right_and_left.pdf
20.How should aortocaval compression be relieved during maternal cardiac arrest?
When the uterine fundus is at or above the umbilicus, the gravid uterus can compress major vessels and impair venous return during resuscitation. AHA recommends manual left uterine displacement while high-quality chest compressions continue with the patient supine. This preserves a firm surface and effective compression mechanics while addressing aortocaval compression. Defibrillation and other indicated resuscitative treatments should not be delayed because of pregnancy or concern about fetal exposure.
Apply it
A patient at 30 weeks develops cardiac arrest. Keep chest compressions underway on a firm supine surface and assign another team member to manual left uterine displacement while standard resuscitation and pregnancy-specific preparations proceed.
Common pitfall: A steep lateral tilt can compromise compression quality. Uterine displacement supplements high-quality resuscitation and must not interrupt compressions, rhythm assessment, or indicated defibrillation during arrest.
2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation
21.When should resuscitative delivery be prepared during maternal arrest?
For maternal cardiac arrest with the fundus at or above the umbilicus, prepare for resuscitative delivery immediately while resuscitation continues. If return of spontaneous circulation does not occur, the goal is delivery by five minutes. Emptying the uterus can improve maternal venous return and resuscitation mechanics; the intervention has a maternal resuscitative purpose. Preparation should occur at the arrest location rather than depend on transfer to an operating room.
Apply it
A third-trimester patient remains pulseless despite initial resuscitation. Activate the resuscitative delivery team immediately and prepare at the bedside, aiming to complete delivery within five minutes rather than starting logistical arrangements at that point.
Common pitfall: Fetal viability does not define the maternal indication for uterine decompression. Waiting to move to an operating room can consume the critical resuscitation interval.
2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation
Obstetric Complicationsnot stated
22.Which findings demand simultaneous cardiopulmonary and hemorrhage responses in suspected amniotic fluid embolism?
Amniotic fluid embolism can present with abrupt hypoxemia, cardiovascular collapse, and rapidly developing coagulopathy around delivery. Management is immediate supportive resuscitation with coordinated obstetric, anesthesia, critical care, and transfusion responses. Severe bleeding may reflect consumptive coagulopathy rather than an isolated mechanical bleeding source. The SMFM checklist emphasizes preparedness for both cardiopulmonary failure and hemorrhage; diagnostic certainty should not delay treatment of the physiologic emergencies already present at the bedside. ABOG places the disease-specific task at MFM3.6.A within Obstetric Complications, with overlapping Critical Care tasks for resuscitation, massive hemorrhage, and coagulopathy.
Apply it
Immediately after delivery, a patient develops profound hypoxemia, hypotension, and diffuse bleeding from puncture sites. Mobilize cardiopulmonary support and massive hemorrhage resources together while evaluating competing causes and correcting the evolving coagulopathy.
Common pitfall: Treating only uterine bleeding can miss the parallel cardiopulmonary collapse. Suspected amniotic fluid embolism also remains a clinical assessment requiring consideration of other catastrophic causes.
SMFM: Checklist for initial management of amniotic fluid embolism—Updated 2026 · ABOG Maternal-Fetal Medicine competency blueprint
23.How should cervical length be measured before treatment decisions?
Cervical length used to guide treatment should be measured transvaginally with a standardized technique. In an asymptomatic singleton pregnancy without prior spontaneous preterm birth, SMFM defines a short cervix as a midtrimester transvaginal length of 25 mm or less. Measurement method matters because bladder filling, probe pressure, and imaging approach can alter the apparent length. A transabdominal impression should therefore not be treated as interchangeable with a properly obtained transvaginal measurement.
Apply it
At an anatomy examination, a transabdominal image suggests a 22-mm cervix. Obtain a standardized transvaginal measurement before counseling about preventive treatment, rather than assigning risk from the abdominal image alone in this pregnancy.
Common pitfall: A precise number is not necessarily a valid measurement. Applying treatment thresholds to a nonstandard imaging technique can produce both unnecessary intervention and missed risk.
SMFM Consult Series #70: Management of short cervix without a history of spontaneous preterm birth
24.How do cervical length, dilation, and obstetric history determine short-cervix treatment?
For an asymptomatic singleton pregnancy without prior spontaneous preterm birth, SMFM recommends vaginal progesterone when transvaginal cervical length is 20 mm or less before 24 weeks; at 21–25 mm, treatment can be considered through shared decision-making. A sonographic length of 10–25 mm without dilation does not routinely warrant cerclage in this population. Dilation changes the clinical problem and requires separate assessment. These recommendations should not be transferred automatically to twins or patients with different obstetric histories.
Apply it
At 21 weeks, a patient with a singleton pregnancy, no prior spontaneous preterm birth, and a closed 18-mm cervix should receive vaginal progesterone rather than routine cerclage based on length alone.
Common pitfall: Do not substitute intramuscular 17-hydroxyprogesterone caproate for vaginal progesterone. The closed-cervix recommendation does not settle management of a dilated cervix.
SMFM Consult Series #70: Management of short cervix without a history of spontaneous preterm birth
25.Why is neuraxial labor analgesia useful in many patients with heart failure?
SMFM recommends neuraxial anesthesia in most patients with heart failure to provide analgesia and limit the effects of labor on cardiac parameters. Pain and the work of labor add cardiovascular stress, so an anesthesia plan is part of cardiac management rather than a comfort decision alone. Coordinate the technique with current hemodynamic stability, anticoagulant exposure, and the delivery plan. Continuous fetal heart rate monitoring is recommended during anesthesia administration, labor, and delivery in pregnant patients with heart failure.
Apply it
A patient with compensated systolic heart failure plans vaginal delivery and receives anticoagulation. Arrange antenatal anesthesia consultation to coordinate neuraxial eligibility and monitoring; discuss whether cardiac risk also supports a limited or assisted second stage.
Common pitfall: Heart failure does not automatically require general anesthesia or cesarean delivery. A recommendation for neuraxial analgesia also does not override anticoagulation-related procedural restrictions or acute hemodynamic instability.
SMFM_Consult_Series__73__Diagnosis_and_management_of_right_and_left.pdf
26.Which findings permit or preclude expectant management after previable PPROM?
SMFM recommends individualized counseling about abortion care and expectant management after previable or periviable PPROM. Offer abortion care to all patients; expectant management is an option only without contraindications. Intraamniotic infection, significant hemorrhage, and fetal demise require delivery or uterine evacuation. Infection may initially occur without fever: uterine tenderness, purulent or malodorous discharge, and maternal or fetal tachycardia require urgent assessment. Suspected infection warrants antibiotics and timely uterine source control without waiting for fever or amniocentesis. Reassess bleeding, infection findings, labor, fetal status, and patient preferences throughout expectant care.
Apply it
At 21 weeks, a previously stable patient choosing expectant care develops uterine tenderness, malodorous discharge, and maternal tachycardia while afebrile. Arrange urgent assessment for intraamniotic infection and initiate indicated antibiotics and delivery or evacuation rather than continuing latency care until fever appears.
Common pitfall: Absence of fever does not establish safety. Latency antibiotics do not make infection, significant hemorrhage, or fetal demise compatible with continued expectant management.
SMFM Consult Series #71: Management of previable and periviable preterm prelabor rupture of membranes · PPROM_Final_Publication.pdf
27.When are antibiotics used during expectant management of early PPROM?
SMFM recommends antibiotics for patients choosing expectant management after PPROM at 24 weeks or later and permits consideration at 20 through 23 weeks and 6 days. These are latency-directed recommendations for patients without an indication for immediate delivery. Clinical infection changes the purpose of antibiotics and may require delivery for source control. Antibiotic eligibility should therefore be linked to gestational age, management goals, and maternal condition rather than rupture alone.
Apply it
A stable patient at 22 weeks chooses expectant management after PPROM. Discuss that antibiotics may be considered at this gestational age, while explaining that new infection or deterioration would require reassessment of the entire plan.
Common pitfall: Latency antibiotics do not make expectant management safe in the presence of uterine sepsis. They also do not determine when neonatal resuscitation will be offered.
28.When should corticosteroids and magnesium begin after periviable PPROM?
After previable or periviable PPROM, antenatal corticosteroids and magnesium sulfate should not be administered simply because membranes have ruptured. SMFM ties their use to the point when neonatal resuscitation and intensive care would be considered appropriate by the clinical team and desired by the patient. These therapies aim to benefit a potentially resuscitated infant, so their timing must fit the neonatal plan. Antibiotic timing follows a separate recommendation and should not be conflated with them.
Apply it
A patient with PPROM is receiving expectant care before the agreed threshold for neonatal resuscitation. Revisit counseling regularly, but defer corticosteroids and magnesium until resuscitation is considered appropriate and is desired by the patient.
Common pitfall: Starting latency antibiotics does not automatically trigger corticosteroids or magnesium. Their different purposes mean that one intervention’s gestational threshold cannot simply be applied to another.
29.Which blood pressure pattern requires urgent treatment, and when does the treatment clock start?
Acute severe hypertension is systolic pressure of at least 160 mm Hg or diastolic pressure of at least 110 mm Hg that persists for approximately 15 minutes. Either component qualifies. Recheck promptly to establish persistence and initiate treatment as soon as reasonably possible. SMFM’s quality metric measures treatment within 60 minutes of the first severe blood pressure measurement, not 60 minutes after confirmation. Prompt confirmation and the treatment deadline are separate requirements; delayed remeasurement must not extend the deadline.
Apply it
A patient has pressures of 166/104 at 10:00 and 164/102 at 10:15. Begin urgent treatment once persistence is established. For the SMFM metric, the 60-minute interval starts at 10:00, so confirmation at 10:15 does not move its endpoint beyond 11:00.
Common pitfall: Both pressure components need not be severe. Do not wait four hours for confirmation or restart the quality-measure clock at the confirming reading.
SMFM: A quality metric for evaluating timely treatment of severe hypertension
30.Why does severe postpartum hypertension remain an emergency?
The maternal risk from severe hypertension continues after delivery. Persistent blood pressure at or above the severe systolic or diastolic threshold warrants the same timely treatment response postpartum as during pregnancy. Birth is not an immediate cure for hypertensive disease, and delayed recognition exposes the patient to preventable neurologic injury. A postpartum assessment should therefore interpret the actual pressure and symptoms rather than downgrade urgency because the fetus has already been delivered.
Apply it
Four days after delivery, a patient reports severe headache and has repeated pressures of 172/112 mm Hg. Arrange immediate evaluation and antihypertensive treatment rather than recommending routine follow-up because the pregnancy has ended.
Common pitfall: Do not attribute a severe postpartum headache to sleep deprivation when severe hypertension is present. Delivery does not remove the need for urgent blood pressure control.
SMFM: A quality metric for evaluating timely treatment of severe hypertension
31.How is surveillance organized for monochorionic diamniotic twins?
Shared placental vascular connections expose monochorionic diamniotic twins to complications that are not expected in the same way with separate placentas. SMFM recommends surveillance for twin-twin transfusion syndrome beginning at 16 weeks and continuing at least every two weeks until delivery. Assessment includes fluid in both sacs and fetal bladder findings, with Doppler evaluation as appropriate. Establishing chorionicity early therefore changes the surveillance schedule rather than merely adding a descriptive ultrasound label.
Apply it
A first-trimester scan establishes monochorionic diamniotic twins. Schedule serial surveillance beginning at 16 weeks, at least every two weeks, and explain why an ordinary singleton-style anatomy scan schedule would miss evolving shared-placenta complications.
Common pitfall: Matching fetal sex does not establish chorionicity. A normal anatomy scan also does not eliminate the need for continuing TTTS surveillance throughout the pregnancy.
SMFM Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence
32.Which fluid pattern distinguishes twin-twin transfusion syndrome?
TTTS arises from unbalanced flow through placental vascular connections in a monochorionic pregnancy. The characteristic ultrasound pattern is oligohydramnios in the donor sac with polyhydramnios in the recipient sac; donor bladder visibility and Doppler abnormalities help stage severity. Growth discordance alone does not establish TTTS. The discriminating feature is the intertwin fluid imbalance in the appropriate placental setting, which directs staging, surveillance intensity, and consideration of fetal intervention.
Apply it
At 20 weeks, monochorionic twins show a deepest vertical pocket of 1 cm around one fetus and 10 cm around the other. Evaluate donor bladder and Dopplers and arrange fetal therapy assessment for suspected TTTS.
Common pitfall: Do not diagnose TTTS from unequal estimated weights alone. Conversely, similar fetal weights do not exclude clinically important fluid imbalance caused by placental vascular connections.
SMFM Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence
33.When is fetoscopic laser the standard TTTS treatment?
For stage II through IV TTTS presenting between 16 and 26 weeks, SMFM recommends fetoscopic laser surgery as standard treatment. Laser targets the placental vascular connections responsible for unbalanced intertwin transfusion. Stage I disease in an asymptomatic patient can often be managed with close surveillance, although additional circumstances may support intervention. The decision therefore depends on disease stage, gestational age, symptoms, and specialist assessment rather than polyhydramnios alone.
Apply it
Monochorionic twins at 21 weeks have TTTS with a nonvisualized donor bladder and otherwise reassuring Dopplers. Refer to a fetal intervention center for fetoscopic laser evaluation instead of offering serial fluid drainage as definitive treatment.
Common pitfall: Amnioreduction relieves excess fluid but does not disconnect the causative placental vessels. The standard stage II–IV recommendation should not be applied automatically to every stage I presentation.
SMFM Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence
34.How does twin anemia-polycythemia sequence differ from TTTS?
Twin anemia-polycythemia sequence reflects chronic intertwin blood transfer producing anemia in one fetus and polycythemia in the other, often without the major fluid discordance of TTTS. SMFM accepts prenatal diagnostic criteria including donor MCA peak systolic velocity above 1.5 multiples of the median with recipient velocity below 1.0, or an intertwin difference above 0.5 multiples of the median. The diagnostic emphasis is discordant blood-flow velocity as a marker of hematologic imbalance.
Apply it
Monochorionic twins have similar fluid volumes, but MCA peak systolic velocities are 1.7 and 0.8 multiples of the median. Evaluate for TAPS rather than dismissing shared-placenta complications because neither sac has marked fluid abnormality.
Common pitfall: Normal fluid volumes do not exclude TAPS. An isolated elevated MCA velocity also requires interpretation in the paired twin context rather than automatic assignment of TTTS.
SMFM Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence
35.How are cholestasis symptoms separated from fetal risk assessment?
Intrahepatic cholestasis of pregnancy is evaluated with serum bile acids and liver transaminases in a patient with suggestive pruritus. SMFM recommends ursodeoxycholic acid as first-line treatment for maternal symptoms. Symptom improvement does not establish that fetal risk has disappeared, because management and delivery timing rely substantially on bile acid concentration and gestational age. Persistent characteristic itching with initially normal studies may justify repeat testing rather than immediate exclusion of the diagnosis.
Apply it
A patient has intense palm and sole itching without a primary rash. Obtain bile acids and transaminases, discuss symptom treatment if cholestasis is diagnosed, and explain why less itching would not independently settle delivery timing.
Common pitfall: Do not use pruritus severity as a substitute for bile acid measurement. Normal initial testing also may precede biochemical abnormalities when characteristic symptoms persist over time.
SMFM Consult Series #53: Intrahepatic cholestasis of pregnancy
36.When should bile acid concentration change delivery timing?
SMFM recommends offering delivery at 36 weeks for intrahepatic cholestasis with total bile acids of at least 100 micromol/L because stillbirth risk increases substantially at this severity. For concentrations below 100, delivery is recommended within 36–39 weeks, individualized within that interval. Preterm delivery before 37 weeks is not recommended for a clinical diagnosis without laboratory confirmation. The key distinction is documented biochemical severity rather than itching alone or response to medication.
Apply it
At 35 weeks, a patient with confirmed cholestasis has bile acids of 118 micromol/L despite improved itching. Discuss delivery at 36 weeks; symptom relief does not move the patient into the lower biochemical risk category.
Common pitfall: A normal fetal surveillance result does not erase the bile-acid-based timing recommendation. Conversely, itching without laboratory confirmation does not justify routine delivery before 37 weeks.
SMFM Consult Series #53: Intrahepatic cholestasis of pregnancy
37.Which evaluations are central after stillbirth?
ACOG–SMFM recommends that stillbirth evaluation include fetal autopsy, gross and histologic examination of the placenta, cord, and membranes, and genetic evaluation. These complementary assessments can reveal different causal pathways; a visible cord finding should not automatically end the investigation. Maternal testing should be guided by the history and presentation. Explaining the purpose and limitations of each component helps families make informed choices, including alternatives when a complete autopsy is declined.
Apply it
After an unexplained fetal death, the family asks whether examination of the fetus alone is sufficient. Explain the distinct value of placental pathology and genetic testing, and offer a respectful discussion of autopsy and available alternatives.
Common pitfall: Do not assume a nuchal cord proves causation. Finding one possible explanation does not automatically make placental examination or genetic evaluation unnecessary after a stillbirth.
ACOG–SMFM Obstetric Care Consensus #10: Management of Stillbirth
38.How should delivery and bereavement care be individualized after fetal death?
After confirmed fetal death, delivery planning depends on gestational age, prior uterine surgery, maternal condition, and patient preferences. Cesarean delivery generally offers no fetal benefit and adds maternal morbidity, so it is reserved for appropriate maternal circumstances. Care also includes compassionate communication, opportunities for memory-making if desired, discussion of evaluation results, and access to bereavement or mental health support. Clinical planning and grief support are simultaneous responsibilities rather than separate competing priorities.
Apply it
A stable patient with fetal death asks for immediate cesarean delivery because labor feels emotionally overwhelming. Explore the concern, explain maternal risks and delivery options, review uterine history, and provide bereavement support throughout shared decision-making.
Common pitfall: Avoid assuming every family wants identical memory-making activities or counseling. Emotional distress deserves active support without automatically making surgery the safest or preferred delivery approach.
ACOG–SMFM Obstetric Care Consensus #10: Management of Stillbirth
Fetal Complications/Prenatal Diagnosisnot stated
39.Which measurements establish fetal growth restriction?
SMFM defines fetal growth restriction as an estimated fetal weight or abdominal circumference below the 10th percentile for gestational age. Either qualifying measurement is sufficient. An estimated weight below the third percentile identifies severe growth restriction and changes risk assessment even if umbilical artery Doppler remains normal. Percentile-based diagnosis depends on reliable gestational dating and an appropriate reference. A single normal overall weight estimate should not override an abdominal circumference that meets the diagnostic criterion.
Apply it
At 30 weeks, estimated fetal weight is at the 14th percentile but abdominal circumference is at the sixth percentile. Diagnose fetal growth restriction and begin the appropriate evaluation rather than dismissing the scan as normal overall growth.
Common pitfall: Do not require both weight and abdominal circumference to be below the 10th percentile. Small size also requires interpretation alongside dating, anatomy, and subsequent placental assessment.
SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
40.When does growth restriction warrant diagnostic genetic evaluation?
Early-onset growth restriction can reflect fetal or chromosomal disease as well as placental dysfunction. SMFM recommends detailed ultrasound for growth restriction diagnosed before 32 weeks and offering diagnostic testing with chromosomal microarray when growth restriction accompanies a malformation or polyhydramnios, regardless of gestational age. Diagnostic testing should also be offered for unexplained isolated growth restriction before 32 weeks. Routine broad infection panels are not a substitute for targeted etiologic assessment.
Apply it
A fetus at 27 weeks has unexplained growth restriction and no obvious structural anomaly. Offer detailed anatomic assessment and discuss amniocentesis with microarray, explaining that isolated early smallness can still have a genetic cause.
Common pitfall: A low-risk screening result does not eliminate all genetic causes of early growth restriction. Avoid automatically labeling every small fetus as having maternal vascular placental disease.
SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
41.How does umbilical artery Doppler guide growth-restriction surveillance?
Umbilical artery Doppler assesses resistance in the placental circulation and helps distinguish uncomplicated small size from more concerning placental dysfunction. After growth restriction is diagnosed, SMFM recommends serial Doppler assessment, generally every one to two weeks initially, with increased frequency for severe growth restriction or abnormal flow. Absent or reversed end-diastolic flow represents greater compromise than elevated resistance with forward flow. Surveillance intensity should therefore respond to the Doppler pattern rather than fetal weight alone.
Apply it
A growth-restricted fetus develops absent end-diastolic umbilical artery flow after previously normal studies. Increase surveillance intensity and reassess delivery planning rather than continuing the prior low-intensity schedule because the estimated weight has changed little.
Common pitfall: Normal umbilical artery flow does not mean growth restriction has resolved. Conversely, worsening Doppler findings can justify escalation even without a dramatic change in estimated fetal weight.
SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
42.When do absent and reversed umbilical artery flow prompt delivery?
In growth restriction, SMFM recommends delivery at 33–34 weeks for absent end-diastolic umbilical artery velocity and at 30–32 weeks for reversed end-diastolic velocity. Reversed flow warrants hospitalization, corticosteroids, heightened fetal monitoring, and consideration of delivery based on the whole clinical picture. These windows balance progressive fetal compromise against prematurity. A superimposed maternal emergency or nonreassuring fetal status can require earlier action, so the windows do not override acute deterioration.
Apply it
At 31 weeks, a growth-restricted fetus has persistent reversed end-diastolic umbilical artery flow. Arrange inpatient management, antenatal preparation, and delivery planning within the recommended window rather than treating the finding like mild elevated placental resistance.
Common pitfall: Do not interchange absent and reversed flow: their recommended delivery windows differ. A reassuring single tracing also does not neutralize persistent reversed placental arterial flow.
SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
43.How is delivery timed when growth restriction has normal Doppler flow?
SMFM recommends delivery at 38–39 weeks when estimated fetal weight is between the third and 10th percentiles and umbilical artery Doppler is normal. Severe growth restriction, defined by estimated weight below the third percentile, supports delivery at 37 weeks even without absent or reversed flow. Decreased diastolic flow without absent or reversed velocity also supports 37-week delivery. The distinction is that normal Doppler does not erase the independent risk associated with extreme smallness.
Apply it
At 36 weeks, one fetus has estimated weight at the seventh percentile with normal Doppler, while another is below the third percentile with normal Doppler. Explain why their anticipated delivery timing differs despite similar flow findings.
Common pitfall: Do not apply the 38–39-week recommendation to every fetus below the 10th percentile. Severe smallness and abnormal Doppler each modify the otherwise later delivery plan.
SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
44.How should MCA Doppler be obtained when fetal anemia is suspected?
Middle cerebral artery peak systolic velocity is the primary noninvasive Doppler assessment for fetal anemia in an at-risk pregnancy. Anemia reduces blood viscosity and increases cardiac output, producing higher flow velocity. SMFM emphasizes sampling near the MCA origin with the insonation angle as close to zero as possible and without angle correction. Technique matters because measurement error can falsely suggest anemia or conceal a clinically important increase in velocity.
Apply it
An alloimmunized pregnancy has a borderline elevated MCA velocity measured at a large insonation angle. Repeat the study with correct sampling and near-zero alignment before interpreting the result as evidence requiring invasive fetal assessment.
Common pitfall: Do not use an arbitrary raw velocity without gestational-age normalization. A technically poor Doppler number should not be treated as equivalent to a valid anemia assessment.
SMFM Clinical Guideline #8: The fetus at risk for anemia—diagnosis and management
45.Which anemia findings warrant fetal blood sampling and transfusion readiness?
SMFM recommends fetal blood sampling with preparation for intrauterine transfusion when a fetus is at significant risk for severe anemia, identified by MCA peak systolic velocity above 1.5 multiples of the median or hydrops. The procedure both confirms severity and allows treatment when appropriate. Referral to a center with fetal therapy expertise is important. Near a gestational age when delivery is safer than the procedure, delivery may be the better definitive intervention.
Apply it
At 27 weeks, an alloimmunized fetus has a technically valid MCA peak systolic velocity of 1.68 multiples of the median. Refer for fetal blood sampling with transfusion capability rather than repeating routine surveillance without escalation.
Common pitfall: A positive maternal antibody screen alone does not establish fetal anemia. Conversely, hydrops is not required before an elevated qualifying MCA velocity warrants invasive evaluation.
SMFM Clinical Guideline #8: The fetus at risk for anemia—diagnosis and management
46.How is surveillance adapted after an intrauterine transfusion?
After intrauterine transfusion, the next procedure is timed using specialist assessment of recurrent anemia rather than a fixed assumption that the fetus remains corrected until delivery. SMFM supports MCA peak systolic velocity for timing a second transfusion, with predicted decline in fetal hemoglobin as an alternative approach. Transfusion changes fetal blood characteristics, so interpretation requires awareness of prior procedures. Delivery timing balances anemia recurrence, procedural risk, gestational age, and other clinical findings.
Apply it
A fetus treated for severe anemia is clinically improved after transfusion. Arrange a specialist plan for repeat Doppler or expected hemoglobin decline and potential repeat intervention rather than returning to ordinary low-risk prenatal surveillance.
Common pitfall: One successful transfusion does not remove the underlying cause of anemia. Avoid scheduling repeated invasive procedures solely by a generic interval without assessing recurrence and gestational context.
SMFM Clinical Guideline #8: The fetus at risk for anemia—diagnosis and management
47.Which serologic pattern supports primary maternal CMV infection?
SMFM identifies primary maternal cytomegalovirus infection through documented IgG seroconversion or the combination of positive IgM, positive IgG, and low IgG avidity. IgM alone is insufficient because it can persist or lack specificity for a recent primary infection. Avidity reflects antibody maturation and helps interpret timing within its limitations. Establishing maternal infection is distinct from diagnosing fetal infection; neither isolated maternal IgM nor symptoms alone proves that the fetus is infected.
Apply it
A patient is referred after an isolated positive CMV IgM result. Review prior serology and obtain the complementary IgG and avidity information needed for interpretation rather than counseling that recent primary infection is already established.
Common pitfall: Do not equate positive IgM with proven recent infection or proven fetal transmission. Maternal serologic classification and fetal diagnostic testing answer related but different questions.
SMFM Consult Series #39: Diagnosis and antenatal management of congenital cytomegalovirus infection
48.When is amniocentesis most informative for fetal CMV diagnosis?
Amniocentesis for CMV testing is most informative after 21 weeks and more than six weeks after the suspected maternal infection, according to SMFM guidance. The interval allows fetal infection and viral excretion into amniotic fluid to become detectable. Testing too early can create false reassurance from a negative result. Maternal serology establishes the maternal infection context, whereas amniotic fluid testing evaluates fetal infection; ultrasound assesses manifestations but cannot exclude infection by itself.
Apply it
Primary maternal CMV infection is established at 18 weeks. Plan diagnostic amniocentesis only after both the gestational-age and infection-interval criteria are satisfied, rather than performing it immediately because the patient wants the earliest possible answer.
Common pitfall: Passing 21 weeks is not enough if the maternal infection was very recent. A normal ultrasound also cannot substitute for appropriately timed fetal infection testing.
SMFM Consult Series #39: Diagnosis and antenatal management of congenital cytomegalovirus infection
49.Why is targeted CMV evaluation different from universal screening?
The cited SMFM CMV guidance does not recommend routine screening of all pregnant patients for primary infection. This differs from evaluating a specific concern such as suggestive ultrasound findings, compatible maternal illness, or documented seroconversion. Targeted evaluation uses the clinical context to select and interpret testing, avoiding the assumption that any positive antibody result defines a fetal diagnosis. Counseling should distinguish the probability of transmission from the severity of disease in an infected fetus.
Apply it
A fetus develops ventriculomegaly despite an otherwise uncomplicated maternal history. Discuss targeted CMV evaluation as part of the fetal workup rather than arguing that the absence of universal screening makes infection testing inappropriate in this case.
Common pitfall: A recommendation against universal screening does not prohibit indicated diagnostic evaluation. Conversely, maternal infection does not predict that every exposed fetus will have severe congenital disease.
SMFM Consult Series #39: Diagnosis and antenatal management of congenital cytomegalovirus infection
50.How are fetal ventriculomegaly measurements categorized?
SMFM categorizes lateral ventricular atrial width as mild ventriculomegaly at 10–12 mm, moderate at 13–15 mm, and severe above 15 mm. These categories matter because associated abnormalities and adverse outcomes become more likely with increasing dilation. Accurate measurement and detailed anatomic assessment precede counseling. A borderline or isolated finding should not be dismissed, but neither should a mild measurement automatically be assigned the prognosis of severe hydrocephalus.
Apply it
An ultrasound reports an atrial width of 14 mm. Explain that this is moderate ventriculomegaly, confirm the measurement, and organize evaluation before providing outcome estimates based on a different category of ventricular enlargement.
Common pitfall: Do not describe every measurement above 10 mm as equally severe. Prognosis depends on degree, associated findings, progression, and the results of the complete evaluation.
SMFM Consult Series #45: Mild fetal ventriculomegaly—diagnosis, evaluation, and management
51.Which investigations should be offered for apparently isolated ventriculomegaly?
When ventriculomegaly is detected, SMFM recommends detailed anatomic evaluation, offering amniocentesis with chromosomal microarray, and testing for CMV and toxoplasmosis regardless of known exposure or maternal symptoms. Fetal MRI may add information when expert interpretation is available, particularly if neurosonographic assessment is limited. The word isolated should remain provisional until evaluation is complete. Follow-up ultrasound also helps determine whether ventricular size is stable, resolving, or progressing.
Apply it
A fetus has 11-mm ventricles and no other finding on the initial anatomy scan. Offer genetic diagnosis and infection testing, explain possible MRI value, and schedule follow-up rather than declaring the finding definitively isolated immediately.
Common pitfall: Lack of maternal fever or known animal exposure does not eliminate the recommended infection evaluation. Low-risk aneuploidy screening also does not replace diagnostic microarray testing.
SMFM Consult Series #45: Mild fetal ventriculomegaly—diagnosis, evaluation, and management
52.How should isolated mild ventriculomegaly affect prognosis and delivery?
After a complete evaluation, isolated mild ventriculomegaly of 10–12 mm usually has a favorable outcome, and counseling should acknowledge that most infants have normal neurodevelopment. Moderate dilation carries greater uncertainty and risk. SMFM recommends determining delivery timing and route by standard obstetric indications rather than mild or moderate ventriculomegaly alone. Prognosis should be updated when follow-up imaging shows progression or newly recognized abnormalities instead of treating the initial label as permanent.
Apply it
A fetus has stable 11-mm ventricles, reassuring detailed imaging, and an unrevealing diagnostic evaluation. Provide favorable but measured counseling and retain standard obstetric delivery planning rather than recommending premature birth solely for the ventricular measurement.
Common pitfall: Favorable prognosis is not a guarantee of normal development. Conversely, an isolated stable mild finding does not itself justify cesarean delivery or routine preterm delivery.
SMFM Consult Series #45: Mild fetal ventriculomegaly—diagnosis, evaluation, and management
Geneticsnot stated
53.Why must a positive cfDNA result be confirmed diagnostically?
Cell-free DNA screening primarily analyzes placental DNA fragments in maternal blood and estimates risk rather than directly establishing the fetal karyotype. Confined placental mosaicism and other biological factors can produce discordance. A positive result warrants genetic counseling, detailed ultrasound assessment, and an offer of diagnostic testing before irreversible decisions. Positive predictive value also depends on baseline prevalence, so high sensitivity does not mean every positive result represents an affected fetus.
Apply it
A patient with a positive trisomy 21 cfDNA result requests an immediate definitive conclusion. Explain the placental basis of screening and discuss CVS or amniocentesis according to gestational age and the specific clinical context.
Common pitfall: Repeating another screening test does not provide the same confirmation as diagnostic testing. A normal ultrasound also cannot independently overturn a positive chromosome screening result.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
54.How should a nonreportable cfDNA result be interpreted?
A nonreportable cfDNA result is not a negative screen. Low fetal fraction and other technical or biological factors can prevent reporting, and test failure is associated with increased aneuploidy risk. SMFM recommends counseling, comprehensive ultrasound evaluation, and offering diagnostic testing. Repeat screening may be considered after individualized discussion, but it can fail again or delay a definitive answer. Gestational age, ultrasound findings, and the patient’s priorities influence the next step.
Apply it
A patient receives a low-fetal-fraction result at 15 weeks and assumes no abnormality was found. Clarify that risk was not successfully assessed, review ultrasound findings, and offer diagnostic testing while discussing the limitations of another blood draw.
Common pitfall: Do not translate no result into low risk. Automatically repeating the test without counseling can delay diagnosis, particularly when gestational age or abnormal ultrasound findings increase urgency.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
55.Why should sex chromosome screening require an informed opt-in?
SMFM recommends making cfDNA screening for sex chromosome aneuploidies an opt-in choice after appropriate counseling. These conditions have variable phenotypes, and screening performance and interpretation differ from common autosomal trisomies. Results can also reveal maternal chromosomal findings or biological discordance rather than a straightforward fetal diagnosis. Consent should therefore address what is being screened, possible outcomes, and confirmatory testing. Interest in fetal sex does not automatically establish informed consent for sex chromosome screening.
Apply it
A patient wants to learn fetal sex but has not considered screening for sex chromosome conditions. Explain the distinction, discuss potential uncertain or discordant findings, and obtain an explicit choice about adding that screening component.
Common pitfall: Do not bundle sex chromosome aneuploidy screening into testing by default. A preference to know fetal sex is not equivalent to understanding the implications of chromosome screening.
56.Which test is preferred when a patient seeks fetal copy-number information?
SMFM does not recommend routine general-population cfDNA screening for microdeletion conditions. When a patient wants information about fetal copy-number variants, diagnostic testing should be offered rather than treating an expanded screening panel as equivalent to chromosomal microarray. Rarity, variable phenotype, and limited predictive performance complicate broad screening. Counseling should match the test to the question: common-trisomy risk assessment and genome-wide diagnostic copy-number analysis provide different information and different degrees of certainty.
Apply it
A patient requests the broadest possible blood screening to exclude microdeletions. Explain the limitations of expanded cfDNA panels and discuss diagnostic sampling with microarray if fetal copy-number information is the actual goal of testing.
Common pitfall: More conditions on a screening menu do not necessarily mean more reliable reassurance. Diagnostic microarray also has limitations and should not be described as excluding every genetic disorder.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
57.When is chromosomal microarray especially useful in prenatal diagnosis?
Chromosomal microarray detects genomic gains and losses, including submicroscopic copy-number variants that conventional karyotyping may miss. SMFM recommends offering microarray when diagnostic genetic analysis is undertaken for a fetus with structural anomalies, and it can replace karyotyping in that setting. Its value is additional resolution for copy-number changes rather than universal detection of all genetic mechanisms. Pretest counseling should explain possible pathogenic findings, uncertain results, and the limits of a normal result.
Apply it
A fetus has a structural cardiac defect despite low-risk cfDNA screening. Offer diagnostic sampling with microarray and explain why screening for common trisomies does not exclude clinically important smaller chromosomal gains or losses in this setting.
Common pitfall: Do not assume a normal screening result makes diagnostic testing redundant after a structural anomaly. Microarray’s added resolution also does not make it a complete single-gene test.
SMFM Consult Series #41: The use of chromosomal microarray for prenatal diagnosis
58.How should uncertain and normal microarray results be explained?
A variant of uncertain significance is a copy-number finding whose clinical implications cannot yet be classified confidently. Parental testing, phenotype review, and expert interpretation may help, but uncertainty may remain. A normal microarray does not exclude every genetic disorder because balanced rearrangements, many sequence variants, and other mechanisms may escape detection. Counseling should distinguish uncertainty about a detected variant from the residual risk remaining after a normal result; neither result supports an absolute prediction of outcome.
Apply it
A fetal microarray identifies a copy-number variant of uncertain significance. Arrange genetics counseling and consider parental studies, while explaining that the laboratory label is not equivalent to either a confirmed pathogenic diagnosis or a benign finding.
Common pitfall: Inheritance from an apparently healthy parent may inform interpretation but does not automatically prove harmlessness. A normal array likewise cannot exclude all single-gene or developmental disorders.
SMFM Consult Series #41: The use of chromosomal microarray for prenatal diagnosis
59.How is autosomal recessive risk calculated for two confirmed carriers?
For a fully penetrant autosomal recessive condition, two heterozygous carriers have a one-in-four chance of an affected child, a one-in-two chance of an unaffected carrier, and a one-in-four chance of an unaffected noncarrier in each pregnancy. These probabilities arise from the four equally likely parental allele combinations. Each conception is a new event, so previous affected or unaffected children do not change the Mendelian probability when parental genotypes are already established.
Apply it
Both partners carry pathogenic variants causing the same autosomal recessive condition. Explain that their next pregnancy has a 25% affected risk even after two unaffected births, assuming the stated genotypes and disease model are correct.
Common pitfall: Do not confuse the 50% carrier probability with the 25% affected probability. Previous outcomes do not use up risk or guarantee a different result next time.
60.How does being an unaffected sibling change recessive carrier probability?
For a fully penetrant autosomal recessive condition in a child of two confirmed carriers, the possible unaffected genotypes are two carrier combinations and one noncarrier combination. Conditioning on being unaffected removes the affected combination, leaving a two-thirds carrier probability. If that untested unaffected sibling has a child with a confirmed carrier, affected-child risk is two-thirds multiplied by one-fourth, or one-sixth. The calculation assumes the diagnosis, parental genotypes, penetrance, and partner carrier status are established.
Apply it
An unaffected adult has an affected sibling and two confirmed carrier parents. Their partner is a confirmed carrier for the same condition. Before testing the adult, calculate an affected-child risk of 2/3 × 1/4 = 1/6.
Common pitfall: Using one-half ignores the information that the sibling is unaffected. Using one-fourth assumes carrier status is already confirmed rather than still being a conditional probability.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Recognize maternal organ dysfunction early, including afebrile sepsis, postpartum heart failure, severe hypertension, and collapse with coagulopathy.
- Coordinate surgical source control, bleeding control, transfusion, and cardiopulmonary support according to the actual cause of deterioration.
- Interpret oxygenation, venous congestion, and cardiac function together; distinguish fluid responsiveness from fluid tolerance.
- Keep population boundaries explicit for short-cervix treatment, cesarean thromboprophylaxis, neuraxial planning, and previable or periviable PPROM counseling.
- Interpret fetal measurements together with gestational age, technique, Doppler findings, anatomy, and the purpose of the test.
- Separate screening probability from diagnostic certainty, and practise conditional Mendelian calculations with clearly stated assumptions.
- Use the full ABOG outline to extend study to additional medical, surgical, anesthetic, placental, ultrasound, and fetal topics; these selections are not the entire examination scope.
A practical preparation plan
1. Map the complete competency outline
Create a study inventory from all five official domains. Mark which tasks these 60 concepts address and identify remaining topics, including additional maternal surgical conditions, anesthetic complications, placental disease, and fetal disorders.
2. Build population-specific decision rules
For each recommendation, write the qualifying population, decisive finding, intervention, and boundary. Contrast a closed short cervix with dilation, uterine with nonuterine sepsis, and screening with diagnostic testing.
3. Practise thresholds and deterioration in paired cases
Compare absent with reversed umbilical artery flow, mild with moderate ventriculomegaly, and bile acids below versus at least 100 micromol/L. Contrast stable PPROM with new infection findings, and distinguish prompt blood pressure confirmation from the treatment clock beginning at the first severe reading.
4. Complete the questions before reviewing explanations
Choose one answer and state the decisive cue. During review, explain why each alternative is less appropriate, then record whether the error involved mechanism, population, measurement, timing, or risk calculation.
5. Use spaced recall and source review
Recall flashcards without looking, revisit missed decisions after increasing intervals, and consult the cited professional guidance for context. Review current ABOG candidate instructions separately for examination logistics.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABOG subspecialty-certification exam blueprint listing
- ABOG Maternal-Fetal Medicine competency blueprint
- SMFM Consult Series #73: Diagnosis and management of right and left heart failure during pregnancy and postpartum
- SMFM Consult Series #69: Hepatitis B in pregnancy: updated guidelines
- SMFM Consult Series #51: Thromboembolism prophylaxis for cesarean delivery
- ADA: Management of Diabetes in Pregnancy—Standards of Care in Diabetes—2026
- SMFM Consult Series #67: Maternal sepsis—full guideline
- SMFM Consult Series #67: Maternal sepsis
- 2025 AHA Guidelines: Adult and Pediatric Special Circumstances of Resuscitation
- SMFM: Checklist for initial management of amniotic fluid embolism—Updated 2026
- SMFM Consult Series #70: Management of short cervix without a history of spontaneous preterm birth
- SMFM Consult Series #71: Management of previable and periviable preterm prelabor rupture of membranes
- SMFM: A quality metric for evaluating timely treatment of severe hypertension
- SMFM Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence
- SMFM Consult Series #53: Intrahepatic cholestasis of pregnancy
- ACOG–SMFM Obstetric Care Consensus #10: Management of Stillbirth
- SMFM Consult Series #52: Diagnosis and management of fetal growth restriction
- SMFM Clinical Guideline #8: The fetus at risk for anemia—diagnosis and management
- SMFM Consult Series #39: Diagnosis and antenatal management of congenital cytomegalovirus infection
- SMFM Consult Series #45: Mild fetal ventriculomegaly—diagnosis, evaluation, and management
- SMFM Consult Series #74: Cell-free DNA screening for aneuploidies—Updated guidance
- SMFM Consult Series #74: Updated cfDNA recommendations
- SMFM Consult Series #41: The use of chromosomal microarray for prenatal diagnosis
- National Human Genome Research Institute: Carrier
- SMFM_Consult_Series__73__Diagnosis_and_management_of_right_and_left.pdf
- c9b1a8b5ba9d32b57d8af8af6fd33ef3.pdf
- SMFM_Consult_Series__41_The_use_of_chromosomal_microarray_for_prenatal_diagnosis.pdf
- PPROM_Final_Publication.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.